Evox raises £35m for exosome therapeutics
Oxford, UK-based Evox Therapeutics has raised £35 million to help advance its exosome-based therapeutics pipeline.
Read More
Tag: OSI
£13m Oxford partnership to accelerate drug innovations
Oxford University, Oxford University Innovation (OUI), Oxford Sciences Innovation (OSI) and Evotec have formed a new public-private alliance to help progress the development of new medicines stemming from Oxford research.
Read More
- Tozorakimab shows significant benefit in two major COPD trials
- Daratumumab becomes first oncology injectable approved for patient administration
- Laigo Bio completes final close of €17m seed financing round
- Axplora announces expansion as newest part of $60m API investment programme
- DNA Script signs SYNTAX distribution agreements with Gencell, BMS and Biostream
